Our Products
Loans
Cards
Insurance
Investment
Stock Market
Electronics Mall
CIBIL Score
Knowledge Centre
Academy 
Calculators
Our Services
My Account
Do not call
En
Vineet Laboratories Ltd. Share Price
Day's Range
Day's Range
Low
₹34.11
High
₹34.80
Price Summary
| Previous Close | ₹34.45 |
|---|---|
| Day's Range | ₹34.11 - ₹34.80 |
| Open | ₹34.80 |
| 52 Week Range | ₹24.01 - ₹43.50 |
| Volume | 15,561 |
| Market Cap | ₹0.00 |
| Previous Close | ₹34.50 |
|---|---|
| Day's Range | ₹34.50 - ₹34.80 |
| Open | ₹34.80 |
| 52 Week Range | ₹23.82 - ₹43.56 |
| Volume | 57 |
| Market Cap | ₹0.00 |
Stocks Summary
| Trade Value ( ₹ in Lacs) | 5.36 |
|---|---|
| Market Cap (₹ in Mn) | 0.00 |
| Dividend Yield(%) | 0.00 |
| Price/Earning (TTM) | 0.00 |
| TTM EPS (₹) | -5.28 |
| P/E Ratio | 0.00 |
| Book Value(₹) | 1.47 |
| PAT Margin (%) | -26.92 |
| Face Value (₹) | 10.00 |
| ROCE(%) | -25.12 |
| Trade Value ( ₹ in Lacs) | 0.02 |
|---|---|
| Market Cap (₹ in Mn) | 0.00 |
| Dividend Yield(%) | 0.00 |
| Price/Earning (TTM) | 0.00 |
| TTM EPS (₹) | -5.28 |
| P/E Ratio | 0.00 |
| Book Value(₹) | 1.47 |
| PAT Margin (%) | -26.92 |
| Face Value (₹) | 10.00 |
| ROCE(%) | -25.12 |
Financials
| Particulars | QTR FY (₹ in Millions) | Annual FY (₹ in Millions) |
|---|---|---|
| Net sales | 180.99 | 1505.91 |
| Expenses | N/A | N/A |
| PBT | -56.74 | 3.63 |
| Operating profit | 0.0 | 0.0 |
| Net profit | -57.07 | 10.27 |
About Vineet Laboratories Ltd.
| Founded | 2016 |
|---|---|
| Managing Director | Gaddam Venkata Ramana |
| NSE Symbol | VINEETLAB |
Peer Comparision
| Stocks Name | Market Cap (Cr)(₹) | Market Price (₹) | 52 Week Low-High (₹) |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | 4,29,468.96 | 1,758.65 | 1,548.00 - 1,548.00 |
| Divi's Laboratories Ltd. | 1,73,304.53 | 6,558.00 | 5,636.50 - 5,636.50 |
| Torrent Pharmaceuticals Ltd. | 1,46,013.82 | 4,347.95 | 3,108.80 - 3,108.80 |
| Apollo Hospitals Enterprise Ltd. | 1,16,410.22 | 8,283.00 | 6,696.50 - 6,696.50 |
| Cipla Ltd. | 1,11,387.62 | 1,371.90 | 1,165.70 - 1,165.70 |
| Zydus Lifesciences Ltd. | 1,08,396.56 | 1,071.90 | 835.50 - 835.50 |
| Dr. Reddy's Laboratories Ltd. | 1,06,381.20 | 1,263.40 | 1,148.40 - 1,148.40 |
| Lupin Ltd. | 1,02,852.99 | 2,242.60 | 1,836.80 - 1,836.80 |
| Mankind Pharma Ltd. | 94,907.18 | 2,332.85 | 1,909.70 - 1,909.70 |
| Max Healthcare Institute Ltd. | 92,414.36 | 961.80 | 903.00 - 903.00 |
No Records Found
Latest News
Piramal Pharma informs about updates
Lupin informs about press release
Corona Remedies informs about investor meetings
Pursuant to Regulation 30 read with Schedule III of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended from time to time, Corona Remedies has informed that the Officials of the Company will be participating in a Non-Deal Roadshow (NDR) to meet Investors on June 08, 2026 and June 09, 2026 at 09:00 am (SST) onwards organized by IIFL Capital in Singapore (1x1). Discussions will be based on publicly available information. No unpublished price sensitive information (UPSI) will be discussed during the said Meetings. This intimation is also being made available on the website of the Company at www.coronaremedies.com.
The above information is a part of company’s filings submitted to BSE.
Shilpa Medicare informs about press release
Pursuant to the compliance with Regulation 30 read with Part A of Schedule III of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, Shilpa Medicare has informed that Shilpa Biocare (‘Biocare’) - a wholly owned subsidiary of the company, intends to make a Strategic Equity Partnership of 30.4% in Gate2Brain (G2B). The details of the above acquisition (as required to be furnished pursuant to Regulation 30 read with Para A of Part A of Schedule III of SEBI Listing Regulations and SEBI Circular No. SEBI/HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated 30th January 2026) are enclosed as Annexure A. The above information is also available on the website of the Company www.vbshilpa.com.
The above information is a part of company’s filings submitted to BSE.
Centenial Surgical Suture informs about newspaper advertisement
In Compliances with Regulation 47 of the SEBI (LODR) Regulations, 2015, Centenial Surgical Suture has informed that it enclosed copies of the Newspaper Advertisement of the Standalone Audited Financial Results of the Company for the quarter and year ended March 31, 2026 published in all the editions of New Hub and in Mumbai Edition of Pratahkal (Regional Newspaper) on June 2, 2026.
The above information is a part of company’s filings submitted to BSE.
No Records Found
Sign in to Unlock Offers!
We don't SPAM
Frequently Asked Questions
The current share price of Vineet Laboratories Ltd. is ₹34.45 as of 2026-06-03.
The market capitalisation of Vineet Laboratories Ltd. is ₹66.26 as of 2026-06-02.
The 1-year return of Vineet Laboratories Ltd. is -0.35% as of 2026-06-03.
The P/E ratio of Vineet Laboratories Ltd. is 0.00 as of 2026-06-03.
The 52-week high and low of Vineet Laboratories Ltd. are ₹43.50 and ₹24.01, respectively, as of 2026-06-03.
Disclaimer
All content and research information displayed on the Site, are obtained from our partner Accord Fintech Private Limited. an authorized data feed vendor of BSE/NSE/MCX/NCDEX exchange. The data is provided on ‘As-Is’ basis and is not a live data feed but a feed with 15 minutes delay or more. Bajaj Markets does not warrant accuracy, completeness, timely availability of the information and data available on the Site. Past performance, when presented, is purely for reference purposes and is not a guarantee of similar future results.
The Services offered on the Site does not constitute investment advice in any manner whatsoever. You shall be solely responsible for any investment decisions made by placing reliance on the information provided on the Site.
Bajaj Markets partners with financial services entities for sourcing leads for services such as DEMAT accounts etc. In case you wish to avail the services, you shall be redirected to partners platform and shall be bound by the terms and conditions, privacy policy governing the said platform.
